Get the Stockscreener App
2.2611
0.94%
-0.0289
Century Therapeutics Inc stock is traded at $2.2611, with a volume of 67,335.
It is down -0.94% in the last 24 hours and up +6.50% over the past month.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
See More
Previous Close:
$2.29
Open:
$2.32
24h Volume:
67,335
Relative Volume:
0.06
Market Cap:
$408.50M
Revenue:
$109.16M
Net Income/Loss:
$-9.57M
P/E Ratio:
-21.49
EPS:
-0.1052
Net Cash Flow:
$-104.72M
1W Performance:
+3.11%
1M Performance:
+6.50%
6M Performance:
+305.23%
1Y Performance:
+304.30%
1-Day Range:
$2.23
$2.35
1-Week Range:
$2.15
$2.36
52-Week Range:
$0.435
$3.04
Century Therapeutics Inc Stock (IPSC) Company Profile
Name
Century Therapeutics Inc
Sector
Industry
Phone
215-981-4000
Address
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Compare IPSC vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
2.265 | 413.01M | 109.16M | -9.57M | -104.72M | -0.1052 |
VRTX
Vertex Pharmaceuticals Inc
|
422.03 | 109.34B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
705.53 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
792.85 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.46 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
295.21 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | TD Cowen | Buy |
| Aug-08-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-27-22 | Initiated | Chardan Capital Markets | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| May-23-22 | Initiated | H.C. Wainwright | Buy |
| May-12-22 | Initiated | William Blair | Mkt Perform |
| Jul-13-21 | Initiated | BofA Securities | Buy |
| Jul-13-21 | Initiated | JP Morgan | Overweight |
| Jul-13-21 | Initiated | Piper Sandler | Overweight |
View All
Century Therapeutics Inc Stock (IPSC) Latest News
How will Century Therapeutics (IPSC) earnings compare to expectations | Q4 2025: Better Than ExpectedViral Trade Signals - Newser
Wall Street Zen Upgrades Century Therapeutics (NASDAQ:IPSC) to Hold - MarketBeat
H.C. Wainwright Increases Century Therapeutics Price Target to Five Dollars - HarianBasis.co
H.C. Wainwright Remains Bullish on Century Therapeutics (IPSC) - Insider Monkey
Century Therapeutics Selected for Oral Presentation of CNTY?813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions - Investing News Network
Century Therapeutics to present diabetes therapy data at ADA - Investing.com
Century Therapeutics to present diabetes therapy data at ADA By Investing.com - Investing.com Canada
Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions - Yahoo Finance
Century Therapeutics (NASDAQ: IPSC) sets 2026 virtual meeting and share authorization vote - Stock Titan
Century Therapeutics (NASDAQ:IPSC) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Century Therapeutics: A Biotech With Interesting Optionality Opportunities (NASDAQ:IPSC) - Seeking Alpha
iPSC-Derived NK Cells Pipeline Set to Transform Cancer Immunotherapy Landscape with 15+ Emerging Therapies and Strong Innovation Momentum from Century Therapeutics, Fate Therapeutics | DelveInsight - Barchart
What is HC Wainwright's Estimate for IPSC Q1 Earnings? - MarketBeat
IPSC Century Therapeutics Inc. posts narrower Q4 2025 loss than expected, shares gain 6.56 percent in daily trading.Margin of Safety - UBND thành phố Hải Phòng
Arrowhead Pharmaceuticals To Rally Over 44%? Here Are 10 Top Analyst Forecasts For Tuesday - Sahm
IPSC Maintained by HC Wainwright & Co. -- Price Target Raised to $5.00 - GuruFocus
Century Therapeutics, Inc. (NASDAQ:IPSC) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
H.C. Wainwright raises Century Therapeutics price target on diabetes therapy potential - Investing.com Canada
Century Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Up 19.3% in March - MarketBeat
[ARS] Century Therapeutics, Inc. SEC Filing - Stock Titan
Century Therapeutics (IPSC) seeks vote to add 150M shares, ratify EY - Stock Titan
Merger Talk: Will Century Therapeutics Inc benefit from seasonalityMarket Activity Summary & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Century Therapeutics (IPSC) awards 88,000 stock options to new director - Stock Titan
Century Therapeutics (IPSC) director Martin Patrick Murphy files initial Form 3 - Stock Titan
CEO Moves: Will Century Therapeutics Inc benefit from current market trendsQuarterly Market Review & Weekly Setup with ROI Potential - baoquankhu1.vn
Aug Action: Is Century Therapeutics Inc undervalued by DCF analysisTake Profit & Expert Curated Trade Setups - baoquankhu1.vn
Panic Selling: What are the future prospects of Century Therapeutics IncBear Alert & Verified Momentum Watchlists - baoquankhu1.vn
Is Century Therapeutics (IPSC) Stock Attractive Now | Price at $2.26, Up 6.10%Top Trending Breakouts - Newser
Century Therapeutics (NASDAQ: IPSC) CSO has shares withheld for taxes - Stock Titan
IPSC Stock Analysis: Century Therapeutics Inc. biotech dips 2.74% to $2.13 in daily trading - Cổng thông tin điện tử tỉnh Tây Ninh
IPSC Stock Analysis: Century Therapeutics Inc. 3.1% dip to $2.19 biotech performance review - Newser
IPSC Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Options Flow: What are the future prospects of Century Therapeutics IncQuarterly Profit Summary & Smart Money Movement Tracker - baoquankhu1.vn
Century Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Update - MarketBeat
VIX Spike: How does Century Therapeutics Inc perform in inflationary periods2026 Momentum & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Century Therapeutics, Inc. (NASDAQ:IPSC) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Century Therapeutics Updates ATM Program to Enhance Liquidity - TipRanks
Century Therapeutics updates equity offering program with $131.6 million remaining - Investing.com Australia
Century Therapeutics (IPSC) files $150M ATM shelf with TD Cowen - Stock Titan
Century Therapeutics (NASDAQ: IPSC) refreshes shelf and $150,000,000 ATM stock program - Stock Titan
Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference - MSN
According to the latest filing disclosed by the U.S. Securities and Exchange Commission (SEC), biotechnology company Century Therapeutics, Inc. has successfully sold common stock worth $18.4 million through investment bank TD Cowen. - Bitget
Weekly Trades: Is Century Therapeutics Inc in a bullish channel2026 Stock Rankings & Fast Entry Momentum Alerts - baoquankhu1.vn
Downgrade Watch: Will Century Therapeutics Inc benefit from seasonality2026 Dividend Review & Breakout Confirmation Alerts - baoquankhu1.vn
IPSC SEC FilingsCentury Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Century Therapeutics reports 2025 results, advances cell therapy pipeline - MSN
Fed Meeting: Will Arch Capital Group Ltd outperform small cap indexes2026 Buyback Activity & Real-Time Volume Surge Alerts - baoquankhu1.vn
Dip Buying: How sensitive is Century Therapeutics Inc to inflationQuarterly Market Summary & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Century Therapeutics Reports 2025 Results, Advances Cell Therapy Pipeline - MyChesCo
Century Therapeutics Hits New 52-Week High at $2.95 - Markets Mojo
Century Therapeutics Hits New 52-Week High of $3.04 Amid Market Fluctuations - Markets Mojo
Century Therapeutics Inc Stock (IPSC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Century Therapeutics Inc Stock (IPSC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Russotti Gregory | See Remarks |
Mar 12 '26 |
Sale |
2.55 |
10,076 |
25,684 |
515,427 |
1.94%
1.54%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):